Anixa Biosciences to Release Phase 1 Breast Cancer Vaccine Data at 39th SITC Annual Meeting

SAN JOSE, Calif., Nov. 6, 2024 -- Anixa Biosciences, Inc., a biotechnology firm focused on cancer treatment and prevention, announced that additional data from the Phase 1 clinical trial of its breast cancer vaccine will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. This presentation is scheduled for 12:15pm CT on November 8, 2024, and will be available on the company's website.

The presentation is titled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC." This detailed analysis will be shared along with a press release from the company at the same time.

The breast cancer vaccine developed by Anixa targets proteins that serve a role during certain life stages but later become inactive, such as the α-lactalbumin protein associated with lactation. Post-lactation, this protein usually disappears from normal tissues but may be present in specific breast cancers. The vaccine works by stimulating the immune system to target this "retired" protein, thus potentially preventing the growth of tumors expressing α-lactalbumin. It includes an adjuvant to enhance the immune system's response against emerging tumors.

Initial data from the Phase 1 trial was presented at the San Antonio Breast Cancer Symposium in December 2023, showing no safety concerns and significant immune responses in most patients. This trial is a collaborative effort with Cleveland Clinic, funded by a grant from the U.S. Department of Defense. Anixa holds the exclusive worldwide license for this breast cancer vaccine technology, which was developed at Cleveland Clinic.

The late Dr. Vincent Tuohy, an esteemed researcher in breast cancer, invented this technology. The Cleveland Clinic, which holds the rights to royalties and commercialization revenues from the vaccine, exclusively licensed the technology to Anixa Biosciences.

Anixa Biosciences is a clinical-stage biotechnology company dedicated to developing treatments and preventative measures for cancer. The company's portfolio includes an ovarian cancer immunotherapy program, developed in partnership with Moffitt Cancer Center, which utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T). In collaboration with Cleveland Clinic, Anixa is also developing vaccines to treat and prevent breast and ovarian cancers. The company is working on additional vaccines targeting various high-incidence cancers like lung, colon, and prostate cancer, aiming to immunize against "retired" proteins expressed in these malignancies.

Anixa's strategic partnerships with prominent research institutions enable the company to explore and commercialize emerging technologies in complementary fields. This collaborative approach allows Anixa to develop cutting-edge treatments and maintain a robust pipeline of innovative cancer therapies.